UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 117

Sortiert nach

Co-agonist therapeutics come of age for obesity

Nature reviews. Endocrinology, 2023-02, Vol.19 (2), p.66

Tan, Tricia M-M

2023

Volltextzugriff (PDF)

100 years of glucagon and 100 more

Diabetologia, 2023-08, Vol.66 (8), p.1378-1394

2023

Volltextzugriff (PDF)

Redefining ITT cortisol thresholds on Abbott platforms to prevent misdiagnosis of adrenal insufficiency

Clinical endocrinology (Oxford), 2024-09, Vol.101 (3), p.195-202

2024

Volltextzugriff (PDF)

Glucagon-based therapy for people with diabetes and obesity: What is the sweet spot?

Peptides (New York, N.Y. : 1980), 2024-06, Vol.176, p.171219-171219, Article 171219

2024

Volltextzugriff (PDF)

Sleeve gastrectomy causes weight‐loss independent improvements in hepatic steatosis

Liver international, 2023-09, Vol.43 (9), p.1890-1900

2023

Volltextzugriff (PDF)

Adaptive infusion of a glucagon‐like peptide‐1/glucagon receptor co‐agonist G3215, in adults with overweight or obesity: Results from a phase 1 randomized clinical trial

Diabetes, obesity & metabolism, 2024-04, Vol.26 (4), p.1479-1491

2024

Volltextzugriff (PDF)

The postprandial secretion of peptide YY1‐36 and 3‐36 in obesity is differentially increased after gastric bypass versus sleeve gastrectomy

Clinical endocrinology (Oxford), 2023-09, Vol.99 (3), p.272-284

2023

Volltextzugriff (PDF)

Safety and efficacy of an extended‐release peptide YY analogue for obesity: A randomized, placebo‐controlled, phase 1 trial

Diabetes, obesity & metabolism, 2021-07, Vol.23 (7), p.1471-1483

2021

Volltextzugriff (PDF)

Quantifying the variability in the assessment of reproductive hormone levels

Fertility and sterility, 2024-02, Vol.121 (2), p.334-345

2024

Volltextzugriff (PDF)

Commentary on “The road to reliable peptide assays is paved with good guidelines”

Clinical endocrinology (Oxford), 2023-06, Vol.98 (6), p.763-765

2023

Volltextzugriff (PDF)

Roux-en-Y Gastric Bypass Increases Glycemic Variability and Time in Hypoglycemia in Patients With Obesity and Prediabetes or Type 2 Diabetes: A Prospective Cohort Study

Diabetes care, 2021-02, Vol.44 (2), p.614-617

2021

Volltextzugriff (PDF)

Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity

Frontiers in endocrinology (Lausanne), 2021-09, Vol.12, p.735019-735019

2021

Volltextzugriff (PDF)

The role of the gut/brain axis in modulating food intake

Neuropharmacology, 2012-07, Vol.63 (1), p.46-56

2012

Volltextzugriff (PDF)

Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity

Biomedicine & pharmacotherapy, 2024-07, Vol.176, p.116888, Article 116888

2024

Volltextzugriff (PDF)

Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia

Diabetes (New York, N.Y.), 2013-04, Vol.62 (4), p.1131-1138

2013

Volltextzugriff (PDF)

A glucagon analogue decreases body weight in mice via signalling in the liver

Scientific reports, 2021-11, Vol.11 (1), p.22577-7, Article 22577

2021

Volltextzugriff (PDF)

Peptide receptor radionuclide therapy for metastatic paragangliomas

Medical oncology (Northwood, London, England), 2016-05, Vol.33 (5), p.47-47, Article 47

2016

Volltextzugriff (PDF)

Adverse outcomes in COVID-19 and diabetes: a retrospective cohort study from three London teaching hospitals

BMJ open diabetes research & care, 2021-01, Vol.9 (1), p.e001858

2021

Volltextzugriff (PDF)

No Guts, No Loss: Toward the Ideal Treatment for Obesity in the Twenty-First Century

Frontiers in endocrinology (Lausanne), 2018-08, Vol.9, p.442-442

2018

Volltextzugriff (PDF)

Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist

Molecular metabolism (Germany), 2021-09, Vol.51, p.101242, Article 101242

2021

Volltextzugriff (PDF)

Design of novel therapeutics targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR) to aid weight loss

Expert opinion on drug discovery, 2023-06, Vol.18 (6), p.659-669

2023

Volltextzugriff (PDF)

Beyond Weight Loss: Establishing a Postbariatric Surgery Patient Support Group—What Do Patients Want?

Journal of obesity, 2018-01, Vol.2018, p.8419120-7

2018

Volltextzugriff (PDF)

Somatostatin Infusion Lowers Plasma Ghrelin without Reducing Appetite in Adults with Prader-Willi Syndrome

The journal of clinical endocrinology and metabolism, 2004-08, Vol.89 (8), p.4162-4165

2004

Volltextzugriff (PDF)

Gastrointestinal Peptides as Therapeutic Targets to Mitigate Obesity and Metabolic Syndrome

Current diabetes reports, 2020-07, Vol.20 (7), p.26-26, Article 26

2020

Volltextzugriff (PDF)

The acute effect of glucagon on components of energy balance and glucose homoeostasis in adults without diabetes: a systematic review and meta-analysis

International Journal of Obesity, 2022-11, Vol.46 (11), p.1948-1959

2022

Volltextzugriff (PDF)

1 – 25 von 117

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(104)
Mit Volltextzugriff
(107)

Publikationsform

Sprache

Englisch
(117)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Co-agonist therapeutics come of age for obesity

100 years of glucagon and 100 more

Redefining ITT cortisol thresholds on Abbott platforms to prevent misdiagnosis of adrenal insufficiency

Glucagon-based therapy for people with diabetes and obesity: What is the sweet spot?

Sleeve gastrectomy causes weight‐loss independent improvements in hepatic steatosis

Adaptive infusion of a glucagon‐like peptide‐1/glucagon receptor co‐agonist G3215, in adults with overweight or obesity: Results from a phase 1 randomized clinical trial

The postprandial secretion of peptide YY1‐36 and 3‐36 in obesity is differentially increased after gastric bypass versus sleeve gastrectomy

Safety and efficacy of an extended‐release peptide YY analogue for obesity: A randomized, placebo‐controlled, phase 1 trial

Quantifying the variability in the assessment of reproductive hormone levels

Commentary on “The road to reliable peptide assays is paved with good guidelines”

Roux-en-Y Gastric Bypass Increases Glycemic Variability and Time in Hypoglycemia in Patients With Obesity and Prediabetes or Type 2 Diabetes: A Prospective Cohort Study

Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity

The role of the gut/brain axis in modulating food intake

Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity

Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia

A glucagon analogue decreases body weight in mice via signalling in the liver

Peptide receptor radionuclide therapy for metastatic paragangliomas

Adverse outcomes in COVID-19 and diabetes: a retrospective cohort study from three London teaching hospitals

No Guts, No Loss: Toward the Ideal Treatment for Obesity in the Twenty-First Century

Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist

Design of novel therapeutics targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR) to aid weight loss

Beyond Weight Loss: Establishing a Postbariatric Surgery Patient Support Group—What Do Patients Want?

Somatostatin Infusion Lowers Plasma Ghrelin without Reducing Appetite in Adults with Prader-Willi Syndrome

Gastrointestinal Peptides as Therapeutic Targets to Mitigate Obesity and Metabolic Syndrome

The acute effect of glucagon on components of energy balance and glucose homoeostasis in adults without diabetes: a systematic review and meta-analysis

Suchergebnisse filtern